At the moment, the pandemic and the effects of the Delta variant are the most important factors impacting penny stocks and blue chips. This has led to new cases popping up around the world, causing people to fear that the pandemic is far from over.
A high level of uncertainty and increased volatility have resulted from these fears. In recent weeks, the blue-chip stock market has largely been flat, but certain under $1 stocks have performed well. Since penny stocks tend not to adhere to the rules, finding decent gains on an intraday basis is relatively easy.
Many view penny stocks as speculative investments due to their volatile trade trend. Investors purchase penny stocks in an attempt to capitalize on an eventual change in stock market trend.
As penny stocks are unpredictable, investing in them always can cost a lot of money. To avoid unpleasant situations it is essential to understand how penny stocks fluctuate.
Research on relevant investments helps investors make informed decisions. By learning their metrics, fundamentals, and developments, penny stocks can be as profitable as any of the Fortune 500 companies.
Salarius Pharmaceuticals (SLRX)
The first stock we’d like to consider is Salarius Pharmaceuticals (NASDAQ: SLRX). In recent years, biotech has gained significant attention in the market. There is no doubt that vaccine stocks have played a significant role. However, immunotherapy firms are rapidly catching up. Cancer treatments are among the company’s specialties. In clinical trials, the company is evaluating how well seclidemstat treatment can treat Ewing sarcoma or hematologic cancer.
The FDA has also granted seclidemstat designation as a Fast Track drug, an Orphan Drug, and a Rare Pediatric Disease.
Keep in mind that the company is doing a lot lately. Recently, Marcus attended Diamond Equity Research’s Emerging Growth Invitational Conference. An overview of the company’s activities was presented by CEO David Arthur, who pointed out recent achievements in clinical research. SLRX stock has seen a slight increase in trading activity since that presentation.
Gold Resource Corporation (GORO)
Another under $1 stock worth checking out is Gold Resource Corporation (GORO). GORO had a bad start to the year. During the past 12 months, its value has plummeted by 55%, a shocking drop. After glancing at the company’s recent results and conference call transcripts, There wasn’t particularly excitement about the stock either. I did, however, find the takeaways to be quite positive, despite my reservation.
Thus, Gold Resource seems to have overcome one of its recent challenges, though silver production may not reach management’s original estimate for 2021 until as late as next year. It was particularly refreshing to hear the management’s honesty and integrity on the call.
Allen Palmiere told the investors about Gold Resource’s struggles this year and why he believes the company can create shareholder value.
The stock has risen 7% over the past few days, so the market seems to have liked the second-quarter results and call. This isn’t a huge improvement, but it might be a start. A turning point in the stock’s performance is possible. So, be on the lookout for this one.
